Ketogenic diet and letrozole to inhibit PI3K signaling in ER plus breast cancer

被引：0
|
作者：
Rexer, Brent
Abramson, Vandana
Nunnery, Sara
Reid, Sonya
Kennedy, Laura
Sanders, Melinda
Bennett, Jessica
Gonzalez-Ericsson, Paula
Sanchez, Violeta
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-02-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-02-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PI3K inhibitors in ER plus breast cancer: Next steps
    Ellis, Matthew J.
    Crowder, Robert
    Ma, Cynthia X.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [2] Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer
    Alves, Carla L.
    Ditzel, Henrik J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [3] In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER plus breast cancer
    O'Brien, Neil A.
    Tomaso, Emmanuelle D.
    Ayala, Raul
    Tong, Luo
    Issakhanian, Shawnt
    Linnartz, Ronald
    Finn, Richard S.
    Hirawat, Samit
    Slamon, Dennis J.
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Autophagy promotes escape from PI3K inhibition in ER plus breast cancer
    Yang, Wei
    Miller, Todd W.
    CANCER RESEARCH, 2015, 75
  • [5] Pharmacodynamics and consequences of PI3K inhibition in ER plus breast tumors
    Yang, W.
    Bean, J.
    Hosford, S.
    Lloye, D.
    Liu, S.
    Salphati, L.
    Pang, J.
    Zhang, X.
    Nannini, M.
    Miller, T. W.
    CANCER RESEARCH, 2016, 76
  • [6] Kinome rewiring upon acquisition of resistance to PI3K inhibitors in ER plus breast cancer
    Griffin, Jacqueline Reedy
    Traphagen, Nicole
    Kettenbach, Arminja
    Miller, Todd
    CANCER RESEARCH, 2020, 80 (16)
  • [7] PI3K pathway mediated splicing defects in ER plus breast cancers
    Ladewig, Erik
    Fairchild, Lauren
    Scaltriti, Maurizio
    Leslie, Christina
    Toska, Eneda
    Baselga, Jose
    CANCER RESEARCH, 2019, 79 (13)
  • [8] Understanding pharmacodynamics and consequences of PI3K inhibition in ER plus breast tumors
    Yang, Wei
    Bean, Jennifer R.
    Dillon, Lloye
    Salphati, Laurent
    Pang, Jodie
    Zhang, Xiaolin
    Pepe, Michelle Nannini
    Miller, Todd W.
    CANCER RESEARCH, 2015, 75
  • [9] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [10] Targeting PI3K overcomes in vivo resistance to everolimus in estrogen receptor (ER plus ) breast cancer
    O'Brien, N. A.
    Tong, L.
    Ayala, R.
    Issakhanian, S.
    McDonald, K.
    Hurvitz, S. A.
    DiTomaso, E.
    Linnartz, R.
    Finn, R. S.
    Hirawat, S.
    Slamon, D. J.
    CANCER RESEARCH, 2013, 73
12345